Prime in GI: Infliximab retreatment; brief bowel syndrome steering

October 14, 2022

1 min learn

After 26 weeks of retreatment with infliximab, 35% of sufferers with Crohn’s illness achieved remission, based on latest information.

Researchers mentioned there was no vital distinction between charges of medical remission in sufferers who beforehand discontinued infliximab because of lack of response vs. intolerance. It was the highest story in gastroenterology final week.

Guidelines_Adobe Stock
The American Gastroenterological Affiliation just lately printed observe suggestions for the administration of brief bowel syndrome. Supply: Adobe Inventory. 

One other high story lined the American Gastroenterological Affiliation’s medical observe suggestions for the administration of brief bowel syndrome.

Learn these and extra high tales in gastroenterology under:

Infliximab retreatment leads to remission in 35% of sufferers with Crohn’s illness

After beforehand discontinuing infliximab, 35% of sufferers with Crohn’s illness achieved remission at 26 weeks with drug retreatment, based on a examine printed in The American Journal of Gastroenterology. Read more.

AGA provides 12 finest observe suggestions for managing brief bowel syndrome

The AGA has launched a medical observe replace and professional overview on the characterization and administration of sufferers with brief bowel syndrome, which just lately was printed in Medical Gastroenterology and Hepatology. Read more.

Q&A: Up to date ACG monograph gives steering for GI care throughout being pregnant, postpartum

The ACG has printed a complement to The American Journal of Gastroenterology with up to date suggestions for the administration of gastrointestinal problems in sufferers who’re pregnant or within the postpartum interval. Read more.

Obeticholic acid flops in part 3 trial for compensated NASH-related cirrhosis

Obeticholic acid didn’t show superiority to placebo for bettering fibrosis in sufferers with compensated cirrhosis because of nonalcoholic steatohepatitis in a part 3 trial, based on an Intercept Prescription drugs press launch. Read more.

Obeticholic acid yields fewer deaths, liver transplants in major biliary cholangitis Sufferers who obtained obeticholic acid for major biliary cholangitis skilled better transplant-free survival in contrast with exterior management sufferers, based on analysis printed in Gastroenterology. Read more.

Share

Leave a Reply